surmount-1 tirzepatide non-diabetic obesity weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

At the moment, the use of such drugs is almost exclusively limited to people with a clear medical need to lose weight

Insomnia is not listed among common adverse reactions in FDA prescribing information, and clinical trials did not identify it as a statistically significant side effect

Ongoing care is handled through monthly refill questionnaires reviewed remotely by a provider

Mounjaro holds 79% of the GLP-1 medication market in the UK, compared to competitor Wegovy with 20%

Current prescribing information from the MHRA and the electronic Medicines Compendium (eMC) does not list ibuprofen as an interacting medication with semaglutide

Severe Allergic Reactions Though rare, allergic reactions can occur